Yamanouchi Pharmaceutical Co., Ltd. has agreed with Daiichi Suntory Pharma Co., Ltd. to terminate the marketing agreement between the two companies regarding the penem-type antibiotic Farom (faropenem sodium) on March 31, 2005. After April 1, 2005, all marketing and detailing activities will be conducted by Maruho Co., Ltd.

Following termination of the agreement, Yamanouchi will transfer the marketing of the products -Farom Tablets 150mg and 200mg and Farom Dry syrup for paediatric. In the fiscal year ended in March 2004, Yamanouchi posted sales of about 3.4 billion yen with these products.